Transplants from the Same Donor
Authors: D. H. Vesole, S. Jagannath
Journal: Annals of Internal Medicine (1992)

Letters1 February 1992Transplants from the Same DonorD. H. Vesole, MD, PhD, S. Jagannath, MDD. H. Vesole, MD, PhDSearch for more papers by this author, S. Jagannath, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-116-3-269 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editors: Spitzer, Zwiebel and Jacobson (1) recently reported the case of a patient who received an HLA-identical bone marrow transplant after receiving a renal allograft from the same donor. The patient developed severe graft-versushost disease with persistent leukemia and died 40 days after transplantation. We report a similar instance of grade-Ill graftversus-host disease treated successfully.A 37-year-old white man with end-stage renal disease secondary to rapidly progressive glomerulonephritis had a kidney transplant from an HLA-identical sibling donor on 31 July 1980. The patient received azathioprine and prednisone therapy until September 1988, when he developed pancytopenia. The azathioprine therapy...References1. SpitzerZwiebelJacobson TJR. Transplants from the same donor [Letter]. Ann Intern Med. 1991;115:498. LinkGoogle Scholar2. AuclercJacquillatAuclercWeilBernard GCMMJ. Posttherapeutic acute leukemia. Cancer. 1979;44:2017-25. CrossrefMedlineGoogle Scholar3. YauLeMaistreZagers JCG. Methylprednisolone, cy and methotrexate for prophylaxis of acute graft-versus-host disease. Bone Marrow Transpl. 1990;5:269-72. MedlineGoogle Scholar4. LaMaistreMeneghettiYau CCJ. Pre-emptive therapy of graft vs. host disease (GVHD) with a pan-T-cell immunotoxin (IT) associated with accelerated engraftment [Abstract]. Antibody, Immunoconjugates and Radiopharmaceuticals. 1990;3:70. Google Scholar5. BlaiseOliveHirn DDM. Prevention of acute GVHD by in vivo use of anti-interleukin-2 receptor monoclonal antibody (33B3.1): a feasibility trial in 15 patients. Bone Marrow Transpl. 1991;8:105-11. MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: University of Arkansas for Medical Sciences Little Rock, AR 72205 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byHematopoietic Cell Transplantation after Solid Organ TransplantationIntersection of Hematopoietic Cell and Solid Organ Transplantation: Lessons Learned and Unanswered QuestionsKidney Transplantation in a Patient with End Stage Renal Disease after Complete Remission of Acute Promyelocytic LeukemiaRenal Graft Rejection After Allogeneic Peripheral-Blood Stem Cell TransplantationShould we be performing more combined hematopoietic stem cell plus solid organ transplants?Discontinuation of immunosuppression for prevention of kidney graft rejection after receiving a bone marrow transplant from the same HLA identical sibling donorOutcomes of Recipients of Both Bone Marrow and Solid Organ Transplants: A Review 1 February 1992Volume 116, Issue 3Page: 269-270KeywordsBone marrowGlomerulonephritisRenal diseasesRenal failureRenal transplantationTransplantation Issue Published: 1 February 1992 PDF downloadLoading ...